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Abstract
Background: Thalassaemia major (TM) patients need regular blood transfusions that lead to accumulation of iron
and death from heart failure. Deferiprone has been reported to be superior to deferoxamine for the removal of
cardiac iron and improvement in left ventricular (LV) function but little is known of their relative effects on the
right ventricle (RV), which is being increasingly recognised as an important prognostic factor in cardiomyopathy.
Therefore data from a prospective randomised controlled trial (RCT) comparing these chelators was retrospectively
analysed to assess the RV responses to these drugs.
Methods: In the RCT, 61 TM patients were randomised to receive either deferiprone or deferoxamine
monotherapy, and CMR scans for T2* and cardiac function were obtained. Data were re-analysed for RV volumes
and function at baseline, and after 6 and 12 months of treatment.
Results: From baseline to 12 months, deferiprone reduced RV end systolic volume (ESV) from 37.7 to 34.2 mL (p =
0.014), whilst RV ejection fraction (EF) increased from 69.6 to 72.2% (p = 0.001). This was associated with a 27% increase
in T2* (p < 0.001) and 3.1% increase in LVEF (p < 0.001). By contrast, deferoxamine showed no change in RVESV (38.1 to
39.1 mL, p = 0.38), or RVEF (70.0 to 69.9%, p = 0.93) whereas the T2* increased by 13% (p < 0.001), but with no change
in LVEF (0.32%; p = 0.66). Analysis of between drugs treatment effects, showed significant improvements favouring
deferiprone with a mean effect on RVESV of -1.82 mL (p = 0.013) and 1.16% for RVEF (p = 0.008). Using regression
analysis the improvement in RVEF at 12 months was shown to be greater in patients with lower baseline EF values (p <
0.001), with a significant difference in RVEF of 3.5% favouring deferiprone over deferoxamine (p = 0.012).
Conclusion: In this retrospective analysis of a prospective RCT, deferiprone monotherapy was superior to
deferoxamine for improvement in RVEF and end-systolic volume. This improvement in the RV volumes and
function may contribute to the improved cardiac outcomes seen with deferiprone.
Introduction
Blood transfusions are standard therapy for patients with
b-thalassaemia major (TM) and prevent death in child-
hood, but although clinical status and short term survival
improve, each unit of blood contains about 200-250 mg
of iron which the body cannot eliminate, which leads to
long term iron accumulation. Patients treated only with
blood transfusions may die in the second and third dec-
ades of life from the complications of iron overload, in
particular heart failure [1,2]. Myocyte damage is related
to the production of reactive oxygen species (ROS)
formed as levels of labile iron rise, which cause oxidative
damage to membranes and mitochondrial respiratory
chain enzyme dysfunction [3,4]. Chelation therapy can
reduce tissue iron levels and the incidence of cardiac
complications, but patients at risk need to be accurately
profiled for appropriate treatment. The cardiovascular
magnetic resonance (CMR) relaxation parameter T2* is
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sensitive to storage tissue iron in haemosiderin because
of the creation of field inhomogeneities by iron particles,
and the clinical adoption of this technique is now wide-
spread as a mainstay of cardiac iron overload assessment
and treatment,[5-7] with important capability to predict
future cardiac events,[8] and evidence of significant bene-
ficial effects on cardiac mortality [9].
Deferoxamine was the first iron chelating agent for clini-
cal use and became standard therapy in the 1970s. It is a
large positively charged lipophobic molecule, is poorly
absorbed by the digestive system and has a short plasma
half life [10,11]. It is therefore administered subcuta-
neously using a portable syringe system usually overnight
typically 5 times per week. This therapy can be very pro-
blematic with poor compliance, and a number of factors
result in long-term cardiac iron accumulation with its use
[12]. The second clinical iron chelator was deferiprone,
which is a much smaller neutrally charged lipophilic mole-
cule which allows good gastrointestinal absorption and
cellular access [10,11]. The plasma half life is longer allow-
ing oral administration with three doses per day. Direct
comparison trials show that deferiprone has greater effi-
cacy than deferoxamine for reducing myocardial iron load-
ing and improving left ventricular (LV) systolic function
[13,14]. However, there is a paucity of data related to the
effects of these chelators on the right ventricle (RV), which
is known to be an important independent predictor of out-
come in dilated cardiomyopathy,[15] and ischaemic heart
disease [16-18]. Recent papers have established the normal
ranges for RV volumetric parameters for non-iron loaded
TM patients and shown a significant relation between T2*
and RV ejection fraction (RVEF), including a small percen-
tage of patients with impaired RVEF but normal LVEF
[19,20]. In order to identify and compare the effects of
deferiprone and deferoxamine, we reanalyzed the CMR
images for the LA16 trial, which was a randomized con-
trolled trial (RCT) comparing the 2 drugs [14]. Our
hypothesis was that deferiprone would improve RV func-
tion more than deferoxamine.
Methods
The LA16 RCT consisted of 61 regularly transfused
patients with TM from 4 centres in Greece and Italy [14].
All patients were previously treated with subcutaneous
deferoxamine monotherapy. Inclusion criteria included a
T2* between 8 and 20 ms and LVEF greater than 56%
based on the lower normal limit for non-anaemic sub-
jects from previously published data [21]. No patient had
heart failure symptoms. Deferiprone was allocated to 29
patients (actual dose 92 mg/kg daily) whilst 32 patients
were allocated to continue with deferoxamine therapy
(dose of 43 mg/kg/day overnight for an average of 5.7
days per week). Written informed consent was obtained
according to local ethics committee approval.
Iron loading and cardiac function was assessed using
CMR. The T2* sequences were installed at the local
CMR facilities, Athens (GE CVi) and Cagliari (GE Signa).
The technique was validated by scanning phantoms of
known T2* and testing intra-site reproducibility by scan-
ning 5 patients twice at the local centre. The same
patients were scanned at the reference site in London
(Siemens Sonata) for inter-site reproducibility. A coeffi-
cient of variation (CV) ≤ 15% was defined as acceptable.
Site inter-study variability was 2.4% for Cagliari and 3.5%
for Athens. Comparison with the reference site yielded
CVs of 1.6% and 9.7% respectively. Volumetric data were
acquired using a steady state free precession sequence
(FIESTA). A set of contiguous short axis cines were
acquired to give complete coverage of both ventricles.
Care was taken to place the basal slice parallel to the
atrioventricular groove. Slice thickness was 8 mm with a
spacing of 10 mm. No patient had a history of, and no
CMR scan showed any features of pulmonary hyperten-
sion (normal pulmonary artery size, no right ventricular
hypertrophy, no systolic septal flattening). Patients were
scanned between 3 and 10 days post transfusion at base-
line, 6 months and 12 months after entering the trial. T2*
values and LV volumetric data were assessed previously
using a CMR viewing and analysis software package
CMRtools (Cardiovascular imaging solutions, London,
UK) [14]. LV function was assessed in the RCT using an
early version of the analysis package in which LV
volumes are quantified manually using direct surface pla-
nimetry, and therefore for consistency we elected to use
the same version of the software to analyze the RV thus
eliminating the need for right sided valve tracking. Care
was taken to include blood volume below the pulmonary
valve. Basal regions with thin, non trabeculated muscle
were considered atrial and were excluded. Papillary mus-
cles were also excluded from the blood pool [22].
Although local blinding to the treatment arm was not
possible due to the nature of drug administration (oral
for deferiprone and subcutaneous for deferoxamine), all
remote scan analysis performed at the core-lab in Lon-
don was fully blinded to treatment. Study treatment was
unblinded on completion of LV and T2* analysis. For the
analysis of the RV volumetric data, all data sets were
anonymized and analyzed in random order using the
same analysis package by experienced operators blinded
to treatment arm and LV response. To assess reproduci-
bility, data-sets with an improvement in RVEF ≥ 5% at 12
months were reprocessed blindly.
Statistical analysis
Continuous variables were compared using a paired t-test.
T2* values were log transformed and changes expressed as
geometric mean with coefficient of variation. Between
groups comparison of drug effects were assessed using a
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repeated measurement ANOVA. Statistical significance
was set at p < 0.05. To quantify reproducibility the coeffi-
cient of variance (CV) was calculated.
Results
Full data on the LA16 study have been published
including the patient demographics,[14] but the impor-
tant trial summary findings are repeated here. In the
deferiprone group 27 patients completed the study; 2
patients withdrew due to adverse events (elevated hepa-
tic enzymes, in one case probably due to cytomegalo-
virus). In the deferoxamine group, 29 patients
completed; 1 patient withdrew secondary to a reduction
in LV function and 2 for personal reasons. The patient
groups were well matched at baseline for cardiac T2*,
LV volumes and function and RV volumes and function
(table 1). Baseline RVEF was within the normal refer-
ence range for thalassaemia patients,[19] except for one
patient in the deferoxamine group (RVEF 1% below the
normal range). Patient compliance was similar for both
groups. Myocardial T2* improved by 18% at 6 months
(p < 0.001) and 27% at 12 months (p < 0.001) in the
deferiprone arm. The LVEF rose by 2.0% from 69.7% at
baseline to 71.7% at 6 months (p < 0.001) and by 3.1%
to 72.7 at 12 months (p < 0.001). With deferoxamine
therapy, T2* improved by 9% at 6 months (p = 0.003)
and by 13% at 12 months (p < 0.001) but LVEF was
unchanged being 68.4% at baseline and 68.7 at 6 months
(+0.52%, p = 0.42) and 68.5 at 12 months (+0.32%, p =
0.66).
In the current analysis, the RV mean volumetric and
T2* values are detailed in table 2. To summarise, in the
deferiprone arm RV end-diastolic volume (EDV) was
stable, RV end-systolic volume (ESV) decreased signifi-
cantly from 37.7 to 34.2 mL at 12 months (p=0.014);
and RVEF increased from 69.6% to 72.2% (p = 0.001).
For the patients on deferoxamine therapy, the changes
in RV parameters from baseline to 12 months showed
no significant difference. Analysis of between drugs
treatment effects using a repeated measurement
ANOVA (table 3) showed significant differences favour-
ing deferiprone for the reduction of RV ESV (p=0.014 at
12 months, Figure 1) and improvement in RVEF (p =
0.008 at 12 months, Figure 2). Non significant differ-
ences between drugs were found for RV EDV. With
regression analysis, the change in RVEF was found to be
inversely related to the baseline EF (p < 0.001) with a
significant difference between drugs favouring deferi-
prone by a mean of 3.5% (95% CI 0.8 to 6.3%; p =
0.012). The reduction in RVESV over 12 months was
also related to the baseline ESV value with borderline
significance (p = 0.051), and there was a significant dif-
ference between drugs favouring deferiprone by a mean
of 4.5 mL more than patients on deferoxamine (95% CI
1.2 to 7.8 mL; p = 0.009). Therefore the patients benefit-
ting most from deferiprone treatment are those with the
lower baseline values of RVEF. The CV for intra-obser-
ver study RVEF measurement was 2.4% at baseline and
2.0% at 12 months. There was no relation between
change in RVEF and change in LVEF (r = 0.3, p = 0.9).
Discussion
RV volumetric and functional parameters have been dif-
ficult to measure using conventional imaging techniques
due to the irregular geometry of the RV chamber, the
size and quantity of the RV trabeculae, and the proxi-
mity of the RV to the chest wall which impairs echocar-
diographic assessment. CMR suffers less from these
drawbacks because of its inherent 3D nature and high
blood to myocardium contrast and is therefore consid-
ered to be the most accurate and reproducible technique
for assessing RV volumes and EF [23,24]. Attention to
correct definition of the basal slice during acquisition
and subsequent analysis is however pivotal. The
improved confidence of measuring RV volumes and
function from CMR and other techniques has assisted
the understanding the importance of the RV in cardiac
disease. RVEF is an important predictor of outcome in
dilated cardiomyopathy, which is both independent of
and incremental to LV EF [15]. The predictive value of
RV function has also been shown in congenital heart
disease,[25-27] chronic systolic dysfunction,[28] and
ischemic heart failure,[16,17,29,30] with RVEF being
shown to be an independent predictor of outcome
Table 1 Baseline values for cardiac volume and function
parameters
Deferiprone Deferoxamine p
No. Patients randomized 28 32
Age 25.1 ± 3.8 26.6 ± 4.7 0.33
Male sex (%) 15 (52) 16 (50) 0.99
Weight (kg) 57.7 ± 7.9 60.6 ± 13.2 0.30
Cardiac parameters
Myocardial T2* (ms) 13.0 (32%) 13.3 (30%) 0.77
LVEDV (mL) 134 ± 32 132 ± 23 0.81
LVESV (mL) 43 ± 14 41 ± 13 0.51
LVEF (%) 69.7 ± 5.4 68.4 ± 4.9 0.34
RVEDV (mL) 122.5 ± 24.9 124.7 ± 27.7 0.75
RVESV (mL) 37.7 ± 11.7 38.1 ± 12.6 0.90
RVEF (%) 69.6 ± 5.2 70.0 ± 5.8 0.79
Biochemical markers
Liver iron concentration (μg/L) 6.16 ± 6.0 6.32 ± 5.8 0.92
Serum ferritin (μg/L) 1791 ± 1029 2795 ± 2441 0.039
Haematology
Transfusional iron (mL/kg/year) 152 ± 43.4 144 ± 44.4 0.53
Haemoglobin level (g/L) 105 ± 12.0 113 ± 11.9 0.023
Values are mean ± SD except for T2* where values are geometric mean with
CV.
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[16,17]. Accordingly, the effects of myocardial iron load-
ing on RV function may be important in thalassaemia
patients.
In the current study, we found a significant improve-
ment in RVEF (increase) and RVESV (reduction) with
deferiprone therapy. These improvements parallel the
previously reported LV response [14]. There was no sig-
nificant increase in RVEDV suggesting loading condi-
tions did not play an important role. A flat RV response
was seen in the deferoxamine group, which again mir-
rors LV behaviour. The between groups analysis showed
superiority for deferiprone over deferoxamine for both
the reduction in RVESV and the increase in RVEF. The
magnitude of improvement in RVEF and reduction in
RVESV were greater for patients with a higher ESV and
lower EF at baseline. Interestingly neither LVEF nor
RVEF improved significantly in the deferoxamine group
despite the improvement in T2*. The cause for this dif-
ference in functional response is not fully understood,
but the explanation may lie in the additional effects of
deferiprone on restoring normal cardiac mitochondrial
function,[31] possibly through effects on reducing reac-
tive oxygen species [32].
There is little other data relating RV function changes
with the iron chelators, but a recently published abstract
relating to a longitudinal trial of the efficacy of defera-
sirox in myocardial siderosis,[33] showed a significant
improvement in myocardial iron levels with an improve-
ment in RVEF at 1 year, but no change in LV function
at 1,[34] 2,[35] and 3 [36] years of follow up. The signif-
icance of this discrepancy between RV and LV response
to deferasirox is not currently clear, though it is possible
that the RV response is an early signal of myocardial
iron clearance as LV compliance and filling pressure
improves.
Limitations
Data acquisition for this study was originally designed to
assess the change in T2* and LV functional parameters
in response to therapy. Therefore no RV long axis
images were obtained to construct 3-dimentional mod-
els for volumetric analysis, but the requirement for this
was removed by using direct manual planimetry for
quantitative analysis of RV volumes. Pulmonary arterial
pressure was not systematically measured using echocar-
diography of the tricuspid regurgitant jet, but here was
no CMR evidence of raised pulmonary artery pressure
in our patients, and pulmonary hypertension is rare in
well treated thalassaemia major [37]. Direct RV mea-
surement of T2* would have been interesting in this
population to compare with changes in RV volumes and
function, however, it is challenging to measure T2* in
the thin wall of the RV and this was not attempted in
the randomized controlled trial.
Conclusions
This study has shown that RVESV decreased and RVEF
improved with deferiprone monotherapy and this bene-
ficial response was superior to deferoxamine. RV volu-
metric and function parameters have in the past been
neglected when reporting the efficacy of iron chelators
Table 2 RV volumetric parameters at baseline, 6 and 12 months (mean ± SD) in the 2 treatment arms
Baseline 6 Months 12 Months p
Deferiprone
T2*, ms 13.0 (32) 15.4 (38) 16.5 (38) < 0.001
RVEDV, mL 122.5 ± 24.9 123.2 ± 26.0 121.3 ± 24.9 0.61
RVESV, mL 37.7 ± 11.7 35.9 ± 11.7 34.2 ± 11.3 0.009
RVSV, mL 84.7 ± 16.5 87.3 ± 16.5 87.1 ± 17.0 0.16
RVEF, % 69.6 ± 5.2 71.4 ± 4.7 72.2 ± 5.3 0.001
Deferoxamine
T2*, ms 13.3 (30) 14.4 (37) 15 (39) <0.001
RVEDV, mL 124.7 ± 27.7 124.4 ± 26.2 128 ± 32.1 0.17
RVESV, mL 38.1 ± 12.6 37.2 ± 12.5 39.1 ± 13.0 0.38
RVSV, mL 86.7 ± 18.0 87.0 ± 15.5 88.9 ± 21.3 0.25
RVEF, % 70.0 ± 5.8 70.8 ± 5.2 69.9 ± 4.6 0.93
The T2* values show the geometric mean and CV. The p value reflects the change from baseline to 12 months.
Table 3 Between drug effect on RV volumetric
parameters showing a significant difference in RV ESV
and RVEF favouring deferiprone.
Treatment effect
Deferiprone-Deferoxamine
Mean 95% CI p
EDV -1.21 -4.44 2.03 0.47
ESV -1.82 -3.27 -0.37 0.014
SV 0.64 -2.02 3.31 0.64
EF 1.16 0.30 2.01 0.008
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p=0.008
Figure 2 The response in the 2 treatment arms for RVEF showed a significant improvement for patients treated with deferiprone,
which was not seen with deferoxamine (12 month difference between drugs p = 0.008).
p=0.014
Figure 1 The response in the 2 treatment arms for RVESV showed a significant improvement for patients treated with deferiprone,
which was not seen with deferoxamine (12 month difference between drugs p = 0.014).
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for myocardial iron overload, and may have independent
prognostic importance, as they do in other cardiac con-
ditions with impaired cardiac function.
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